Nationwide survey finds nearly half of people with inherited retinal disease waited more than five years for genetic ...

Key Points Interested in Opus Genetics, Inc.? Here are five stocks we like better. Opus Genetics highlighted a broad ...

Please provide your email address to receive an email when new articles are posted on . Patients with inherited retinal diseases may present with seemingly routine conditions. Look for comorbid ...

Opus Genetics, Inc. (Nasdaq: IRD) (“Opus Genetics” or the “Company”), a clinical-stage biopharmaceutical company developing gene therapies to restore vision and prevent blindness in patients with ...

RESEARCH TRIANGLE PARK, N.C., May 28, 2026 (GLOBE NEWSWIRE) -- (Nasdaq: IRD), a clinical-stage biopharmaceutical company developing gene therapies to restore vision and prevent blindness in patients ...

Researchers at the University of Oklahoma are advancing the fight against inherited retinal diseases (IRDs) with new genetic research that aims to improve diagnoses and lay the groundwork for future ...

Two new compounds may be able to treat retinitis pigmentosa, a group of inherited eye diseases that cause blindness. The compounds were identified using a virtual screening approach. Two new compounds ...

An international team led by University of Manchester scientists has created the most detailed picture yet of how genetic differences shape the way the human eye works. The breakthrough could help ...

Opus Genetics, Inc., a clinical-stage biotechnology company focusing on gene therapies for inherited retinal diseases, announced upcoming presentations at various scientific conferences in May 2025.

A new study challenges what's long been assumed about genetic variants thought to always cause inherited blindness. Investigators from Mass General Brigham used large public biobanks to determine that ...